Analyst consensus rating
ENDRA Life Sciences Analyst Rating: none
NDRA is rated none by 1 analysts with a $25.00 target. As of 2026-08-17.
Direct answer
ENDRA Life Sciences's consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $25.00.
Forecast evidence checked August 17, 2026.
Get free ENDRA Life Sciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $4.47
- Average price target
- $25.00
- High price target
- $25.00
- Low price target
- $25.00
- Low target gap
- +459.3%
- Target upside
- +459.3%
- High target gap
- +459.3%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- August 17, 2026
- Valid through
- August 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ENDRA Life Sciences?
ENDRA Life Sciences has a verified none consensus. The same dataset has an average price target of $25.00.
How far are ENDRA Life Sciences's low and high targets from the recorded price?
The low target implies +459.3%, while the high target implies +459.3%.
How many analysts are included in ENDRA Life Sciences's consensus?
The verified consensus includes 1 analysts.
How is ENDRA Life Sciences's target upside or downside calculated?
The average target of $25.00 is divided by the recorded price of $4.47, then one is subtracted to produce +459.3%. This does not guarantee a future return.
When was ENDRA Life Sciences's analyst forecast verified?
The data was verified on 2026-08-17. The dataset is valid through 2026-08-24.